Hello, I'm Frank Colin, anchor worldwide exchange. Every morning on the show, we have a stock pick. Today's pick, Thermo Fisher.It came from Sarat Sethi of DCLA. He likes healthcare in general, but likes this stock in particular that's known for laboratory equipment and software because he says it's trading below its historic valuation. He also believes there's a number of factors that are not priced into this stock.One of them, a trade deal. The stock traded lower this year because of a negative tariff imp ...

Let's bring in Sarra Seth, managing partner and portfolio manager at Douglas C. Lane and Associates. He's also a CNBC contributor.Satra, good morning. Good to see you. >> Good morning, Frank.>> All right, we got to start with Nvidia. Uh, looking like it could open above $5 trillion for a market cap when at the opening bell. What does that say to you about the AI trade in this stock in particular.>> Look, I think the AI trade is going very strong. Nvidia's announced quite a few agreements. You you've seen it ...

Core Viewpoint - The Bay Area Semiconductor Industry Ecosystem Expo 2025 (Bay Chip Expo 2025) will take place from October 15-17 at the Shenzhen Convention Center, focusing on the efficient integration of the entire semiconductor industry chain, with a core emphasis on wafer manufacturing [2][4]. Group 1: Event Overview - The expo will cover an exhibition area of 60,000 square meters, showcasing cutting-edge technologies and solutions from over 600 high-quality semiconductor companies, expected to attract more than 60,000 professional visitors [2][12]. - The event aims to create an "ecological display circle" that deeply connects key segments such as IC design, advanced packaging, and compound semiconductors, encompassing EDA/IP, semiconductor equipment, materials, core components, wafer manufacturing, and packaging testing [5][6]. Group 2: Industry Collaboration - The wafer manufacturing exhibition area is one of the largest, featuring top companies like ASML, AMAT, and Lam Research, showcasing their strengths and innovations in wafer manufacturing [8][16]. - The exhibition promotes a complete technical display matrix from "equipment - materials - manufacturing," facilitating the upgrade of the industry chain from "single-point innovation" to "systemic collaboration" [10]. Group 3: International Participation - The number of international exhibitors has increased by over 50% compared to previous years, indicating a significant enhancement in internationalization levels, driven by the vast prospects of the Chinese market [12][18]. - International companies will present cutting-edge technologies across the entire chip design, wafer manufacturing, and packaging testing chain, providing a valuable platform for domestic companies to engage in deep technical exchanges with global industry leaders [14][16]. Group 4: Ecosystem Development - The expo embodies an open and inclusive spirit of cooperation, evolving into a truly global semiconductor industry event, promoting a "win-win" ecosystem through mutual advantages and collaboration [16][20]. - The event aims to effectively integrate global semiconductor resources, deepen supply-demand connections, and foster collaborative innovation, achieving a balance between "display" and "empowerment" [16][20].

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the **Global Healthcare** industry, particularly the integration of **AI/ML technologies** within various healthcare sectors, including medical devices, healthcare services, therapeutics, and diagnostics [2][11][22]. Core Insights and Arguments 1. **AI Use Cases in Healthcare**: - AI is being utilized for better drug/product design, increased labor efficiency, and process automation within healthcare systems [2][3]. - The potential for AI to transform drug/device development is significant, with expectations of cost-efficient drug discovery and improved clinical trial execution [3][5]. 2. **Labor Shortages and Operational Efficiency**: - A projected global healthcare worker shortage of over **10 million** by **2030** highlights the need for technologies that enhance operational efficiencies [4]. - AI technologies could help mitigate physician burnout, which affects approximately **1.76 million** workers [4]. 3. **Impact on Diagnosis and Treatment Rates**: - AI innovations in diagnostics could lead to earlier and more accurate diagnoses, potentially increasing treatment rates, especially in populations with historically low screening rates [5]. 4. **Investment Trends**: - AI/ML investments are growing within healthcare, with **25%** of global VC capital in healthcare allocated to AI/ML in **1H25**, up from a **15%** average in previous periods [12][16]. - In the US, AI/ML deals in healthcare saw a **16% YoY** increase, despite an overall decline in healthcare VC investments [18]. 5. **Sector-Specific Insights**: - **Medical Devices**: AI is expected to enhance trial and product design, manufacturing, and labor productivity [22]. - **Healthcare Services**: Improved data analytics and process automation are anticipated to enhance operational efficiencies [25]. - **Therapeutics**: Drug development and trial optimization are seen as key areas for AI adoption [26]. 6. **Company-Specific Developments**: - Companies like **Edwards Lifesciences** and **Medtronic** are actively piloting AI initiatives to improve patient identification and treatment processes [28]. - **Quest Diagnostics** reported a **3%** annual productivity increase attributed to AI, while **LabCorp** noted over **$100 million** in savings from AI-driven cost-cutting measures [34]. Additional Important Content - The call highlighted the increasing frequency of AI mentions in healthcare earnings calls, with **10%** of calls in **1Q25** discussing AI, particularly among providers and medical devices [11]. - The report emphasizes that while AI presents numerous opportunities, evidence of its impact on revenue and margins remains limited and early-stage across various subsectors [22][29]. - The analysts noted that companies slow to adopt AI may face challenges in maintaining competitiveness in the evolving healthcare landscape [30][34]. This summary encapsulates the key points discussed in the conference call, providing insights into the current state and future potential of AI in the healthcare industry.

Company Overview - Avantor is a life science tools company providing critical products and services to life sciences and advanced technology industries, with segments including laboratory solutions and bioscience production [1] - The laboratory solutions segment accounts for 67% of revenue, while bioscience production makes up 33% [4] Financial Performance - Avantor's share price has declined by 53.96%, 59.69%, and 43.41% over the past 1, 3, and 5 years, respectively [5] - The company projected earnings per share above $2 for 2025, but current estimates stand at 96 cents per share, with an EBITDA margin of 11.8% compared to a target of over 20% [5] Management and Operational Issues - Engine Capital highlights significant underperformance attributed to a flawed leadership team and a complex organizational structure leading to high turnover, including the CEO and CFO [6] - The laboratory solutions segment has lost profitability and market share due to poor capital allocation decisions, with $3.8 billion spent on acquisitions during the pandemic peak [7] Strategic Recommendations - Engine Capital urges Avantor's board to focus on operational excellence, organic growth, cost reduction, and portfolio optimization, including potential divestitures of non-core assets [3][12] - The company should consider using free cash flow for share repurchases and debt reduction rather than pursuing further M&A [13] Valuation and Market Position - Avantor's revenue of $6.8 billion is spread across 6 million stock keeping units, indicating a need for portfolio optimization [11] - The company trades at roughly 8x EBITDA, while peers trade at higher multiples, suggesting potential for value unlocking through strategic actions [17] Future Outlook - Engine believes that with proper implementation of changes, Avantor shares could be valued between $22 and $26 by the end of 2027 [15] - If standalone improvements are not viable, Engine suggests considering a sale of the company or splitting its segments [16]

Let's do final trades. Josh Brown, what you got. Post is down seven points from before it reported its best earnings quarter ever.I think the stocks are screaming by in the low 40s. Okay, thank you for that, Sat. What about you.Uh, sticking with Transdime. I think it's really cheap at these levels. Thank you very much.Uh, Carrie Firestone, Thermo Fisher, it's at the 200 day moving average and things will get better. Federal funding is restored to universities. Okay.And Joe T, I like you talking about the 20 ...

Group 1 - The analyst has over 15 years of experience in investing and has provided research services to mid-sized hedge funds with assets under management between $100 million and $500 million [1] - The focus is on medium-term investing, targeting ideas with catalysts to unlock value or short selling in case of downside catalysts [1] - The analyst has a generalist approach but has primarily analyzed the industrial, consumer, and technology sectors, indicating higher conviction in these areas [1]

We have a committee move to get to. Bill just bought Thermoffisher. Um, this obviously used to be a kind of a favorite uh high quality name in terms of uh secular growth lab sciences kind of products, research stuff.Um, and yet it's fall on hard times. What do you like. Yeah, I mean it's it really kind of based out atove around $400 and had a tre tremendous earnings report about a week and a half ago.um we've been really underweight healthcare and it's found it as a good opportunity to start to see some gre ...

Market Concerns & Risks - The inflation-adjusted PE ratio matches the peak of the dot-com bubble, indicating potential overvaluation [2] - The 10 largest cap companies are more expensive than during the dot-com bubble, suggesting caution in owning these stocks [2] - Historically high spread between 30-year mortgage rates and 10-year Treasury yields adds uncertainty [7] - Cyclically adjusted PE ratio (Shiller PE ratio) broke records, historically leading to poor S&P returns over 3-5 years [10][11] - S&P 500's momentum may reverse, hurting the largest cap stocks due to index selling [11][12] Investment Opportunities - Small-cap companies (around $10 billion) are attractive due to lack of liquidity and being undervalued [5] - Homebuilder stocks are attractive when sentiment is low due to anticipatory nature of the market [6] - Energy and healthcare sectors may offer better investment opportunities [4] - Companies punished for mistakes (e.g., Target, Merck) may present opportunities [5] Company Specifics - Smeed Capital Management sold Berkshire Hathaway due to premium associated with Buffett's involvement and its large-cap nature [9] - Thermo Fisher's earnings were better than feared, suggesting potential undervaluation in the healthcare space [8]

Core Viewpoint - The merger between BD and Waters aims to create a new leader in the life sciences and diagnostics sector, targeting the expanding precision medicine and biopharmaceutical markets with a total transaction value of approximately $17.5 billion [1][4][17]. Recent Developments and Future Outlook - In February 2025, BD announced plans to divest its biosciences and diagnostics business, followed by the merger agreement with Waters on July 14, 2025, with completion expected by the end of Q1 2026, pending regulatory approval [3]. - The global life sciences instrument market is projected to reach $85 billion by 2030, with a CAGR of approximately 5-6%, highlighting significant growth opportunities in precision medicine, biopharmaceuticals, and multiplex diagnostics [3]. Strategic Motives - The transaction reflects a strategic shift for both companies: BD focuses on core medical technologies, while Waters seeks to transform its business model from single instrument sales to recurring revenue in diagnostics and services [4][5]. - BD's divestiture aligns with its strategy to concentrate resources on core products like syringes and smart medical devices, which are closely tied to hospital workflows [4][7]. Industry Landscape and Market Opportunities - The merger occurs in a competitive environment where major players like Thermo Fisher and Danaher have expanded through acquisitions, creating pressure on mid-sized analytical instrument companies [5]. - The new company is expected to leverage BD's established presence in Asia, particularly in China and Japan, to enhance global expansion potential [3]. Technical Complementarity - The merger is significant for its technical complementarity, enabling a full chain capability from molecular analysis to cellular detection, which is crucial for biopharmaceutical development and personalized medicine [9][10]. Synergies and Collaborative Value - BD and Waters anticipate achieving approximately $200 million in cost synergies and $290 million in revenue synergies post-merger, but the focus is on the broader industry collaborative value rather than just financial metrics [11]. - The integration of technologies and market strategies is expected to enhance their competitive edge in the life sciences sector [12][16]. Product and Service Integration - The combined entity will offer a comprehensive solution that integrates molecular diagnostics and analytical capabilities, addressing the full spectrum of biopharmaceutical research and clinical validation needs [15]. - The merger allows for the development of complex multiplex testing products, enhancing diagnostic speed and accuracy [15]. Conclusion - The merger between BD and Waters represents a transformative move in the life sciences and diagnostics industry, positioning the new company as a key player in advancing precision medicine and biopharmaceutical innovation [17].